These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. More evidence of declining incidence of amyloidosis associated with inflammatory rheumatic diseases. Vasala M; Immonen K; Kautiainen H; Hakala M Scand J Rheumatol; 2010 Nov; 39(6):461-5. PubMed ID: 20560815 [TBL] [Abstract][Full Text] [Related]
5. [Incidence of secondary amyloidosis in chronic inflammatory rheumatism]. Roselló Pardo R; Solé Arqués M Med Clin (Barc); 1986 Oct; 87(13):525-8. PubMed ID: 3491266 [No Abstract] [Full Text] [Related]
6. [The problem of amyloidosis in rheumatic diseases]. Dilşen N; Ulagay I Turk Tip Cemiy Mecm; 1968; 34(11):671-81. PubMed ID: 5306477 [No Abstract] [Full Text] [Related]
8. Renal amyloidosis secondary to chronic rheumatic inflammatory disease. Thysell H; Berglund K Am J Kidney Dis; 1996 Jun; 27(6):916. PubMed ID: 8651258 [No Abstract] [Full Text] [Related]
9. [Systemic complications in patients with rheumatism and collagen disease and their treatment]. Eguchi K Nihon Naika Gakkai Zasshi; 2002 Mar; 91 Suppl():106-10. PubMed ID: 11989247 [No Abstract] [Full Text] [Related]
10. Does renal function influence plasma levels of advanced glycation and oxidation protein products in patients with chronic rheumatic diseases complicated by secondary amyloidosis? Rysavá R; Kalousová M; Zima T; Dostál C; Merta M; Tesar V Kidney Blood Press Res; 2007; 30(1):1-7. PubMed ID: 17191033 [TBL] [Abstract][Full Text] [Related]
11. [Treatment and prognosis of secondary amyloidosis in the course of rheumatic disease]. Wiland P; Szechiński J Pol Arch Med Wewn; 2003 Jul; 110(1):797-802. PubMed ID: 14682217 [No Abstract] [Full Text] [Related]
12. Systemic amyloidosis: a challenge for the rheumatologist. Perfetto F; Moggi-Pignone A; Livi R; Tempestini A; Bergesio F; Matucci-Cerinic M Nat Rev Rheumatol; 2010 Jul; 6(7):417-29. PubMed ID: 20531382 [TBL] [Abstract][Full Text] [Related]
13. No improvement in survival of patients with amyloidosis associated with inflammatory rheumatic diseases -- data from the Finnish national registry for kidney diseases. Immonen K; Finne P; Hakala M; Kautiainen H; Pettersson T; Grönhagen-Riska C J Rheumatol; 2008 Jul; 35(7):1334-8. PubMed ID: 18609734 [TBL] [Abstract][Full Text] [Related]
14. [Rheumatic diseases and liver involvement]. Gentilini P; Salvadori G; Smorlesi C; Pinzani M; Alterini B Minerva Med; 1981 Dec; 72(50):3463-7. PubMed ID: 6119655 [No Abstract] [Full Text] [Related]
15. [Renal manifestations of rheumatic diseases]. Schwarting A; Märker-Hermann E Z Rheumatol; 2005 Feb; 64(1):18-25. PubMed ID: 15756496 [TBL] [Abstract][Full Text] [Related]
16. [Hip in inflammatory rheumatic diseases]. Bosnić D; Mayer M; Potocki K Reumatizam; 2004; 51(2):36-8. PubMed ID: 15554376 [TBL] [Abstract][Full Text] [Related]
17. [Neurological manifestations of rheumatic disorders]. Schneider M; Fischer-Betz R Z Rheumatol; 2004 Apr; 63(2):101-3. PubMed ID: 15112087 [No Abstract] [Full Text] [Related]
18. Amyloidosis in the rheumatic diseases. Dhillon V; Woo P; Isenberg D Ann Rheum Dis; 1989 Aug; 48(8):696-701. PubMed ID: 2675784 [No Abstract] [Full Text] [Related]
19. [The systemic characteristics of inflammatory rheumatic diseases and their significance for diagnosis, differential diagnosis and therapy]. Hartl PW Z Orthop Ihre Grenzgeb; 1984; 122(4):436-47. PubMed ID: 6332433 [No Abstract] [Full Text] [Related]